178 related articles for article (PubMed ID: 28828923)
1. Impact of model and dose uncertainty on model-based selection of oropharyngeal cancer patients for proton therapy.
Bijman RG; Breedveld S; Arts T; Astreinidou E; de Jong MA; Granton PV; Petit SF; Hoogeman MS
Acta Oncol; 2017 Nov; 56(11):1444-1450. PubMed ID: 28828923
[TBL] [Abstract][Full Text] [Related]
2. Impact of setup and range uncertainties on TCP and NTCP following VMAT or IMPT of oropharyngeal cancer patients.
Hamming-Vrieze O; Depauw N; Craft DL; Chan AW; Rasch CRN; Verheij M; Sonke JJ; Kooy HM
Phys Med Biol; 2019 Apr; 64(9):095001. PubMed ID: 30921775
[TBL] [Abstract][Full Text] [Related]
3. A Quantitative Clinical Decision-Support Strategy Identifying Which Patients With Oropharyngeal Head and Neck Cancer May Benefit the Most From Proton Radiation Therapy.
Brodin NP; Kabarriti R; Pankuch M; Schechter CB; Gondi V; Kalnicki S; Guha C; Garg MK; Tomé WA
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):540-552. PubMed ID: 30496877
[TBL] [Abstract][Full Text] [Related]
4. A Model-Based Approach to Predict Short-Term Toxicity Benefits With Proton Therapy for Oropharyngeal Cancer.
Rwigema JM; Langendijk JA; Paul van der Laan H; Lukens JN; Swisher-McClure SD; Lin A
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):553-562. PubMed ID: 30625409
[TBL] [Abstract][Full Text] [Related]
5. Dose uncertainties in IMPT for oropharyngeal cancer in the presence of anatomical, range, and setup errors.
Kraan AC; van de Water S; Teguh DN; Al-Mamgani A; Madden T; Kooy HM; Heijmen BJ; Hoogeman MS
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):888-96. PubMed ID: 24351409
[TBL] [Abstract][Full Text] [Related]
6. Patient selection for proton therapy using Normal Tissue Complication Probability with deep learning dose prediction for oropharyngeal cancer.
Huet-Dastarac M; Michiels S; Rivas ST; Ozan H; Sterpin E; Lee JA; Barragan-Montero A
Med Phys; 2023 Oct; 50(10):6201-6214. PubMed ID: 37140481
[TBL] [Abstract][Full Text] [Related]
7. The impact of treatment accuracy on proton therapy patient selection for oropharyngeal cancer patients.
Arts T; Breedveld S; de Jong MA; Astreinidou E; Tans L; Keskin-Cambay F; Krol ADG; van de Water S; Bijman RG; Hoogeman MS
Radiother Oncol; 2017 Dec; 125(3):520-525. PubMed ID: 29074078
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of an automated clinical decision system with deep learning dose prediction and NTCP model for prostate cancer proton therapy.
Chen M; Pang B; Zeng Y; Xu C; Chen J; Yang K; Chang Y; Yang Z
Phys Med Biol; 2024 May; 69(11):. PubMed ID: 38718814
[No Abstract] [Full Text] [Related]
9. Model-based approach for quantitative estimates of skin, heart, and lung toxicity risk for left-side photon and proton irradiation after breast-conserving surgery.
Tommasino F; Durante M; D'Avino V; Liuzzi R; Conson M; Farace P; Palma G; Schwarz M; Cella L; Pacelli R
Acta Oncol; 2017 May; 56(5):730-736. PubMed ID: 28281862
[TBL] [Abstract][Full Text] [Related]
10. Normal tissue complication probability modeling to guide individual treatment planning in pediatric cranial proton and photon radiotherapy.
Dell'Oro M; Wilson P; Short M; Hua CH; Merchant TE; Bezak E
Med Phys; 2022 Jan; 49(1):742-755. PubMed ID: 34796509
[TBL] [Abstract][Full Text] [Related]
11. Methods for Reducing Normal Tissue Complication Probabilities in Oropharyngeal Cancer: Dose Reduction or Planning Target Volume Elimination.
Samuels SE; Eisbruch A; Vineberg K; Lee J; Lee C; Matuszak MM; Ten Haken RK; Brock KK
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):645-52. PubMed ID: 27681761
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the effect of setup uncertainty reduction and adaptation to geometric changes on normal tissue complication probability using online adaptive head and neck intensity modulated proton therapy.
Lalonde A; Bobić M; Sharp GC; Chamseddine I; Winey B; Paganetti H
Phys Med Biol; 2023 May; 68(11):. PubMed ID: 37164020
[No Abstract] [Full Text] [Related]
13. Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: A case-matched control analysis.
Holliday EB; Kocak-Uzel E; Feng L; Thaker NG; Blanchard P; Rosenthal DI; Gunn GB; Garden AS; Frank SJ
Med Dosim; 2016; 41(3):189-94. PubMed ID: 27158021
[TBL] [Abstract][Full Text] [Related]
14. Inclusion of a variable RBE into proton and photon plan comparison for various fractionation schedules in prostate radiation therapy.
Ödén J; Eriksson K; Toma-Dasu I
Med Phys; 2017 Mar; 44(3):810-822. PubMed ID: 28107554
[TBL] [Abstract][Full Text] [Related]
15. Proton therapy and oral mucositis in oral & oropharyngeal cancers: outcomes, dosimetric and NTCP benefit.
Nangia S; Gaikwad U; Noufal MP; Sawant M; Wakde M; Mathew A; Chilukuri S; Sharma D; Jalali R
Radiat Oncol; 2023 Jul; 18(1):121. PubMed ID: 37468950
[TBL] [Abstract][Full Text] [Related]
16. Using a reduced spot size for intensity-modulated proton therapy potentially improves salivary gland-sparing in oropharyngeal cancer.
van de Water TA; Lomax AJ; Bijl HP; Schilstra C; Hug EB; Langendijk JA
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e313-9. PubMed ID: 21708427
[TBL] [Abstract][Full Text] [Related]
17. NTCP reduction for advanced head and neck cancer patients using proton therapy for complete or sequential boost treatment versus photon therapy.
Jakobi A; Stützer K; Bandurska-Luque A; Löck S; Haase R; Wack LJ; Mönnich D; Thorwarth D; Perez D; Lühr A; Zips D; Krause M; Baumann M; Perrin R; Richter C
Acta Oncol; 2015; 54(9):1658-64. PubMed ID: 26340301
[TBL] [Abstract][Full Text] [Related]
18. Applying a variable relative biological effectiveness (RBE) might affect the analysis of clinical trials comparing photon and proton therapy for prostate cancer.
Marteinsdottir M; Paganetti H
Phys Med Biol; 2019 Jun; 64(11):115027. PubMed ID: 31082810
[TBL] [Abstract][Full Text] [Related]
19. Impact of the NTCP modeling on medical decision to select eligible patient for proton therapy: the usefulness of EUD as an indicator to rank modern photon vs proton treatment plans.
Chaikh A; Calugaru V; Bondiau PY; Thariat J; Balosso J
Int J Radiat Biol; 2018 Sep; 94(9):789-797. PubMed ID: 29878849
[TBL] [Abstract][Full Text] [Related]
20. The price of robustness; impact of worst-case optimization on organ-at-risk dose and complication probability in intensity-modulated proton therapy for oropharyngeal cancer patients.
van de Water S; van Dam I; Schaart DR; Al-Mamgani A; Heijmen BJ; Hoogeman MS
Radiother Oncol; 2016 Jul; 120(1):56-62. PubMed ID: 27178142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
